Thiazolidinediones News and Research

RSS

Thiazolidinediones are adjunctive therapies for diabetes mellitus (type 2) and related diseases.

Insulin resistance drug with anti-inflammatory effects reduces risk factors

A drug, which reduces insulin resistance and also may have anti-inflammatory and other effects on blood vessels, lowered cardiovascular risk factors in patients with diabetes more than another diabetes medicine, even though both drugs improved blood sugar control equally, according to a new study (PDF) in the June 21, 2005, issue of the Journal of the American College of Cardiology.

21 Jun 2005

Study shows why thiazolidinediones cause edema and helps understand role of kidneys in hypertension

In related discoveries with far-reaching implications for treating diabetes and understanding hypertension, University of Utah researchers have learned why thiazolidinediones (TZDs), a major anti-diabetes drug, cause edema and also have found a new pathway critical to fluid metabolism. Identification of this pathway may help understand fundamental mechanisms of blood pressure control.

19 Jun 2005

Researchers describe emerging strategy for prevention, early treatment of Type 2 diabetes

Type 2 diabetes may be significantly delayed or prevented through medication that takes the load off of the body's delicate insulin-producing cells, according to a study released today by researchers at the Keck School of Medicine of the University of Southern California.

12 Jun 2005

Keeping fit lowers C-Reactive protein in people with metabolic syndrome

In people with signs of metabolic syndrome, including high blood pressure, high triglycerides, high cholesterol, elevated blood glucose and obesity, physical activity appears to reduce a marker for inflammation which has been linked to heart disease

16 Nov 2004

Rosiglitazone helps boost the effectiveness of a treatment for opening clogged arteries

Rosiglitazone, a drug taken to help improve blood sugar levels, also helps boost the effectiveness of a treatment for opening clogged arteries, according to a study in the November issue of Diabetes Care.

25 Oct 2004

Combination treatment may help type 2 diabetes patients

New research presented by Peter Weissman, M.D., from the University of Miami, at the 64th Annual Scientific Sessions of the American Diabetes Association shows that combination treatment with rosiglitazone maleate and metformin significantly improves certain markers of cardiovascular disease risk in patients with type 2 diabetes compared to metformin alone.

6 Jun 2004

Study of three treatments of type 2 diabetes in children and teens has begun in US

A clinical study comparing three treatments of type 2 diabetes in children and teens has begun in 12 medical centers and their affiliated sites around the country, HHS Secretary Tommy G. Thompson announced today.

22 Mar 2004

Thiazolidinediones News and Research

Insulin resistance drug with anti-inflammatory effects reduces risk factors

Study shows why thiazolidinediones cause edema and helps understand role of kidneys in hypertension

Researchers describe emerging strategy for prevention, early treatment of Type 2 diabetes

Keeping fit lowers C-Reactive protein in people with metabolic syndrome

Rosiglitazone helps boost the effectiveness of a treatment for opening clogged arteries

Combination treatment may help type 2 diabetes patients

Study of three treatments of type 2 diabetes in children and teens has begun in US

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News